Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
49
ADXN Quote, Financials, Valuation and Earnings
Last price:
$7.70
Seasonality move
:
34.52%
Day range:
$7.69 - $8.28
52-week range:
$6.51 - $12.05
Dividend yield:
0%
P/E ratio:
0.77x
P/S ratio:
36.54x
P/B ratio:
1.32x
Volume:
3.1K
Avg. volume:
6.1K
1-year change:
2.3%
Market cap:
$9.8M
Revenue:
$465.6K
EPS (TTM):
-$8.44
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
ACIU
AC Immune SA
|
$509K | -$0.22 | 18.61% | -6.92% | $9.01 |
|
CRSP
CRISPR Therapeutics AG
|
$2.6M | -$1.09 | -89.16% | -180.62% | $81.33 |
|
MOLN
Molecular Partners AG
|
-- | -$0.46 | -100% | -0.76% | $10.63 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.51 | 29.38% | -70.04% | $400.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADXN
Addex Therapeutics Ltd.
|
$7.99 | $30.00 | $9.8M | 0.77x | $0.00 | 0% | 36.54x |
|
ACIU
AC Immune SA
|
$3.13 | $9.01 | $314.9M | -- | $0.00 | 0% | 61.04x |
|
CRSP
CRISPR Therapeutics AG
|
$55.08 | $81.33 | $5.2B | -- | $0.00 | 0% | 125.63x |
|
MOLN
Molecular Partners AG
|
$4.23 | $10.63 | $158.2M | -- | $0.00 | 0% | 187.52x |
|
ONC
BeOne Medicines Ltd.
|
$312.39 | $400.06 | $34.6B | 601.10x | $0.00 | 0% | 6.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
MOLN
Molecular Partners AG
|
1.58% | 1.720 | 1.39% | 9.08x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
MOLN
Molecular Partners AG
|
-$658.5K | -$14.9M | -48.43% | -49.28% | -2407.93% | -$12.8M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Addex Therapeutics Ltd. vs. Competitors
-
Which has Higher Returns ADXN or ACIU?
AC Immune SA has a net margin of -3178.71% compared to Addex Therapeutics Ltd.'s net margin of -1688.87%. Addex Therapeutics Ltd.'s return on equity of -73.84% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About ADXN or ACIU?
Addex Therapeutics Ltd. has a consensus price target of $30.00, signalling upside risk potential of 275.47%. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 188.23%. Given that Addex Therapeutics Ltd. has higher upside potential than AC Immune SA, analysts believe Addex Therapeutics Ltd. is more attractive than AC Immune SA.
Company Buy Ratings Hold Ratings Sell Ratings ADXNAddex Therapeutics Ltd.0 0 0 ACIUAC Immune SA4 0 0 -
Is ADXN or ACIU More Risky?
Addex Therapeutics Ltd. has a beta of 1.573, which suggesting that the stock is 57.32% more volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock ADXN or ACIU?
Addex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addex Therapeutics Ltd. pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADXN or ACIU?
Addex Therapeutics Ltd. quarterly revenues are $62K, which are smaller than AC Immune SA quarterly revenues of $1.2M. Addex Therapeutics Ltd.'s net income of -$2M is higher than AC Immune SA's net income of -$19.8M. Notably, Addex Therapeutics Ltd.'s price-to-earnings ratio is 0.77x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addex Therapeutics Ltd. is 36.54x versus 61.04x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADXNAddex Therapeutics Ltd.36.54x 0.77x $62K -$2M ACIUAC Immune SA61.04x -- $1.2M -$19.8M
-
Which has Higher Returns ADXN or CRSP?
CRISPR Therapeutics AG has a net margin of -3178.71% compared to Addex Therapeutics Ltd.'s net margin of -11973.12%. Addex Therapeutics Ltd.'s return on equity of -73.84% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About ADXN or CRSP?
Addex Therapeutics Ltd. has a consensus price target of $30.00, signalling upside risk potential of 275.47%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 47.66%. Given that Addex Therapeutics Ltd. has higher upside potential than CRISPR Therapeutics AG, analysts believe Addex Therapeutics Ltd. is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings ADXNAddex Therapeutics Ltd.0 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is ADXN or CRSP More Risky?
Addex Therapeutics Ltd. has a beta of 1.573, which suggesting that the stock is 57.32% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock ADXN or CRSP?
Addex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addex Therapeutics Ltd. pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADXN or CRSP?
Addex Therapeutics Ltd. quarterly revenues are $62K, which are smaller than CRISPR Therapeutics AG quarterly revenues of $889K. Addex Therapeutics Ltd.'s net income of -$2M is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Addex Therapeutics Ltd.'s price-to-earnings ratio is 0.77x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addex Therapeutics Ltd. is 36.54x versus 125.63x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADXNAddex Therapeutics Ltd.36.54x 0.77x $62K -$2M CRSPCRISPR Therapeutics AG125.63x -- $889K -$106.4M
-
Which has Higher Returns ADXN or MOLN?
Molecular Partners AG has a net margin of -3178.71% compared to Addex Therapeutics Ltd.'s net margin of -2408.81%. Addex Therapeutics Ltd.'s return on equity of -73.84% beat Molecular Partners AG's return on equity of -49.28%.
Company Gross Margin Earnings Per Share Invested Capital ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M MOLNMolecular Partners AG-- -$0.40 $122M -
What do Analysts Say About ADXN or MOLN?
Addex Therapeutics Ltd. has a consensus price target of $30.00, signalling upside risk potential of 275.47%. On the other hand Molecular Partners AG has an analysts' consensus of $10.63 which suggests that it could grow by 151.28%. Given that Addex Therapeutics Ltd. has higher upside potential than Molecular Partners AG, analysts believe Addex Therapeutics Ltd. is more attractive than Molecular Partners AG.
Company Buy Ratings Hold Ratings Sell Ratings ADXNAddex Therapeutics Ltd.0 0 0 MOLNMolecular Partners AG3 1 0 -
Is ADXN or MOLN More Risky?
Addex Therapeutics Ltd. has a beta of 1.573, which suggesting that the stock is 57.32% more volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ADXN or MOLN?
Addex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addex Therapeutics Ltd. pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADXN or MOLN?
Addex Therapeutics Ltd. quarterly revenues are $62K, which are larger than Molecular Partners AG quarterly revenues of --. Addex Therapeutics Ltd.'s net income of -$2M is higher than Molecular Partners AG's net income of -$14.8M. Notably, Addex Therapeutics Ltd.'s price-to-earnings ratio is 0.77x while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addex Therapeutics Ltd. is 36.54x versus 187.52x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADXNAddex Therapeutics Ltd.36.54x 0.77x $62K -$2M MOLNMolecular Partners AG187.52x -- -- -$14.8M
-
Which has Higher Returns ADXN or ONC?
BeOne Medicines Ltd. has a net margin of -3178.71% compared to Addex Therapeutics Ltd.'s net margin of 8.84%. Addex Therapeutics Ltd.'s return on equity of -73.84% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About ADXN or ONC?
Addex Therapeutics Ltd. has a consensus price target of $30.00, signalling upside risk potential of 275.47%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 28.06%. Given that Addex Therapeutics Ltd. has higher upside potential than BeOne Medicines Ltd., analysts believe Addex Therapeutics Ltd. is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ADXNAddex Therapeutics Ltd.0 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is ADXN or ONC More Risky?
Addex Therapeutics Ltd. has a beta of 1.573, which suggesting that the stock is 57.32% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock ADXN or ONC?
Addex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Addex Therapeutics Ltd. pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADXN or ONC?
Addex Therapeutics Ltd. quarterly revenues are $62K, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Addex Therapeutics Ltd.'s net income of -$2M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Addex Therapeutics Ltd.'s price-to-earnings ratio is 0.77x while BeOne Medicines Ltd.'s PE ratio is 601.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Addex Therapeutics Ltd. is 36.54x versus 6.98x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADXNAddex Therapeutics Ltd.36.54x 0.77x $62K -$2M ONCBeOne Medicines Ltd.6.98x 601.10x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
